Bone destruction

Also known as: Lytic lesion / Osteolysis / Resorption bone increased

DrugDrug NameDrug Description
DB06643DenosumabA RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures.
DrugDrug NamePhaseStatusCount